JP2004516009A - アミノアシルｔＲＮＡシンテターゼ - Google Patents

アミノアシルｔＲＮＡシンテターゼ Download PDF

Info

Publication number: JP2004516009A
Authority: JP; Japan
Prior art keywords: polynucleotide; polypeptide; atrs; seq; antibody
Prior art date: 2000-07-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2002509465A

Other languages

English (en)

Japanese (ja)

Inventor

リー、アーンスティーン・エイ

タング、ワイ・トム

リュ、デュング・アイナ・エム

トリボレー、キャサリーン・エム

ガンディー、アミーナ・アール

リュ、ヤン

ボーグン、マライア・アール

ワレン、ブリジット、エイ

ソーントン、マイケル

ユエ、ヘンリー

ジャクソン、ジェニファー・エル

アービズ、チャンドラ・エス

エリオット、ビッキー・エス

サンガベル、カビサ

ランクマール、ジャヤラクシミ

チョーラ、ナリンダー・ケイ

ヤオ、モニーク・ジー

Original Assignee

インサイト・ゲノミックス・インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-07

Filing date

2001-06-29

Publication date

2004-06-03

2001-06-29 Application filed by インサイト・ゲノミックス・インコーポレイテッド filed Critical インサイト・ゲノミックス・インコーポレイテッド

2004-06-03 Publication of JP2004516009A publication Critical patent/JP2004516009A/ja

Status Pending legal-status Critical Current

Links

108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 title claims abstract description 338
102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 title claims abstract description 337
108091033319 polynucleotide Proteins 0.000 claims abstract description 302
102000040430 polynucleotide Human genes 0.000 claims abstract description 302
239000002157 polynucleotide Substances 0.000 claims abstract description 302
238000000034 method Methods 0.000 claims abstract description 212
230000014509 gene expression Effects 0.000 claims abstract description 129
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 57
201000010099 disease Diseases 0.000 claims abstract description 53
239000005557 antagonist Substances 0.000 claims abstract description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 235
102000004196 processed proteins & peptides Human genes 0.000 claims description 218
229920001184 polypeptide Polymers 0.000 claims description 211
210000004027 cell Anatomy 0.000 claims description 152
239000012634 fragment Substances 0.000 claims description 137
150000001875 compounds Chemical class 0.000 claims description 113
239000000523 sample Substances 0.000 claims description 97
125000003275 alpha amino acid group Chemical group 0.000 claims description 85
150000007523 nucleic acids Chemical class 0.000 claims description 81
238000009396 hybridization Methods 0.000 claims description 73
125000003729 nucleotide group Chemical group 0.000 claims description 72
239000002773 nucleotide Substances 0.000 claims description 71
230000000694 effects Effects 0.000 claims description 68
239000000203 mixture Substances 0.000 claims description 64
238000012360 testing method Methods 0.000 claims description 61
150000001413 amino acids Chemical class 0.000 claims description 54
230000027455 binding Effects 0.000 claims description 50
102000039446 nucleic acids Human genes 0.000 claims description 39
108020004707 nucleic acids Proteins 0.000 claims description 39
230000000295 complement effect Effects 0.000 claims description 38
238000011282 treatment Methods 0.000 claims description 35
239000012472 biological sample Substances 0.000 claims description 30
238000012216 screening Methods 0.000 claims description 30
230000002163 immunogen Effects 0.000 claims description 20
241001465754 Metazoa Species 0.000 claims description 19
239000000556 agonist Substances 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 15
231100000419 toxicity Toxicity 0.000 claims description 15
230000001988 toxicity Effects 0.000 claims description 15
230000008859 change Effects 0.000 claims description 13
230000002829 reductive effect Effects 0.000 claims description 11
238000001514 detection method Methods 0.000 claims description 9
230000009870 specific binding Effects 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
238000012408 PCR amplification Methods 0.000 claims description 5
230000002018 overexpression Effects 0.000 claims description 5
230000009261 transgenic effect Effects 0.000 claims description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
210000004408 hybridoma Anatomy 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
230000005875 antibody response Effects 0.000 claims 2
238000002405 diagnostic procedure Methods 0.000 claims 2
230000003053 immunization Effects 0.000 claims 2
210000000628 antibody-producing cell Anatomy 0.000 claims 1
241000282414 Homo sapiens Species 0.000 abstract description 31
239000013604 expression vector Substances 0.000 abstract description 23
239000003795 chemical substances by application Substances 0.000 abstract description 11
230000002159 abnormal effect Effects 0.000 abstract description 10
108090000623 proteins and genes Proteins 0.000 description 182
102000004169 proteins and genes Human genes 0.000 description 104
235000018102 proteins Nutrition 0.000 description 96
239000002299 complementary DNA Substances 0.000 description 92
108020004414 DNA Proteins 0.000 description 62
239000013598 vector Substances 0.000 description 62
235000001014 amino acid Nutrition 0.000 description 57
108091028043 Nucleic acid sequence Proteins 0.000 description 55
229940024606 amino acid Drugs 0.000 description 52
238000002869 basic local alignment search tool Methods 0.000 description 45
108091032973 (ribonucleotides)n+m Proteins 0.000 description 43
239000013615 primer Substances 0.000 description 39
210000001519 tissue Anatomy 0.000 description 38
108091034117 Oligonucleotide Proteins 0.000 description 35
238000004458 analytical method Methods 0.000 description 35
238000003752 polymerase chain reaction Methods 0.000 description 29
238000003556 assay Methods 0.000 description 25
238000004422 calculation algorithm Methods 0.000 description 25
238000002493 microarray Methods 0.000 description 25
239000013612 plasmid Substances 0.000 description 25
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
238000000746 purification Methods 0.000 description 20
238000013518 transcription Methods 0.000 description 20
239000003814 drug Substances 0.000 description 19
238000005516 engineering process Methods 0.000 description 19
230000002068 genetic effect Effects 0.000 description 19
230000035897 transcription Effects 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
230000001105 regulatory effect Effects 0.000 description 18
239000000758 substrate Substances 0.000 description 18
230000000875 corresponding effect Effects 0.000 description 17
230000006870 function Effects 0.000 description 16
238000000338 in vitro Methods 0.000 description 16
230000014616 translation Effects 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 15
108020001507 fusion proteins Proteins 0.000 description 15
102000037865 fusion proteins Human genes 0.000 description 15
238000012163 sequencing technique Methods 0.000 description 15
238000013519 translation Methods 0.000 description 15
238000006467 substitution reaction Methods 0.000 description 14
108020004635 Complementary DNA Proteins 0.000 description 13
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
108020004566 Transfer RNA Proteins 0.000 description 13
230000000692 anti-sense effect Effects 0.000 description 13
239000000243 solution Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
241000700605 Viruses Species 0.000 description 12
238000003199 nucleic acid amplification method Methods 0.000 description 12
239000000126 substance Substances 0.000 description 12
108010038807 Oligopeptides Proteins 0.000 description 11
102000015636 Oligopeptides Human genes 0.000 description 11
125000000539 amino acid group Chemical group 0.000 description 11
230000003321 amplification Effects 0.000 description 11
210000000349 chromosome Anatomy 0.000 description 11
239000005090 green fluorescent protein Substances 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
230000008569 process Effects 0.000 description 11
241000124008 Mammalia Species 0.000 description 10
239000004698 Polyethylene Substances 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
238000001415 gene therapy Methods 0.000 description 10
239000012528 membrane Substances 0.000 description 10
230000035772 mutation Effects 0.000 description 10
-1 polyethylene Polymers 0.000 description 10
241000894007 species Species 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
108010026552 Proteome Proteins 0.000 description 9
230000001363 autoimmune Effects 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 9
238000002372 labelling Methods 0.000 description 9
230000002265 prevention Effects 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
238000001890 transfection Methods 0.000 description 9
241000701161 unidentified adenovirus Species 0.000 description 9
238000005406 washing Methods 0.000 description 9
208000023275 Autoimmune disease Diseases 0.000 description 8
241000894006 Bacteria Species 0.000 description 8
108020004705 Codon Proteins 0.000 description 8
108700024394 Exon Proteins 0.000 description 8
241000282412 Homo Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
108091093037 Peptide nucleic acid Proteins 0.000 description 8
241000700584 Simplexvirus Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000010367 cloning Methods 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000001939 inductive effect Effects 0.000 description 8
208000027866 inflammatory disease Diseases 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
238000013507 mapping Methods 0.000 description 8
239000003550 marker Substances 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
238000002864 sequence alignment Methods 0.000 description 8
239000007787 solid Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
230000002588 toxic effect Effects 0.000 description 8
238000012546 transfer Methods 0.000 description 8
108010070675 Glutathione transferase Proteins 0.000 description 7
108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 7
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
210000001124 body fluid Anatomy 0.000 description 7
239000000872 buffer Substances 0.000 description 7
201000011510 cancer Diseases 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
239000011521 glass Substances 0.000 description 7
210000000688 human artificial chromosome Anatomy 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
231100000331 toxic Toxicity 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
108010058060 Alanine-tRNA ligase Proteins 0.000 description 6
102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 6
108090000994 Catalytic RNA Proteins 0.000 description 6
102000053642 Catalytic RNA Human genes 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
238000000137 annealing Methods 0.000 description 6
239000010839 body fluid Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
239000007850 fluorescent dye Substances 0.000 description 6
230000028993 immune response Effects 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000002502 liposome Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
229960004452 methionine Drugs 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
230000006798 recombination Effects 0.000 description 6
238000005215 recombination Methods 0.000 description 6
238000011160 research Methods 0.000 description 6
108091092562 ribozyme Proteins 0.000 description 6
230000007017 scission Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
230000009466 transformation Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
238000001712 DNA sequencing Methods 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
108091034057 RNA (poly(A)) Proteins 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
102000054765 polymorphisms of proteins Human genes 0.000 description 5
239000002987 primer (paints) Substances 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
241000701447 unidentified baculovirus Species 0.000 description 5
241001529453 unidentified herpesvirus Species 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 4
239000003155 DNA primer Substances 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 4
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 4
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
208000003250 Mixed connective tissue disease Diseases 0.000 description 4
101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
108010002747 Pfu DNA polymerase Proteins 0.000 description 4
ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
101710176177 Protein A56 Proteins 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
241000714474 Rous sarcoma virus Species 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
208000009621 actinic keratosis Diseases 0.000 description 4
238000007792 addition Methods 0.000 description 4
229940125644 antibody drug Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
239000000185 hemagglutinin Substances 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
239000003446 ligand Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000006166 lysate Substances 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
238000011002 quantification Methods 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000032258 transport Effects 0.000 description 4
230000008733 trauma Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
101150067361 Aars1 gene Proteins 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000710929 Alphavirus Species 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 3
241000222120 Candida <Saccharomycetales> Species 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010042407 Endonucleases Proteins 0.000 description 3
241001635598 Enicostema Species 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
241000288906 Primates Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
241000710961 Semliki Forest virus Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
102100036407 Thioredoxin Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
241000723873 Tobacco mosaic virus Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000003491 array Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
210000002459 blastocyst Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
230000009918 complex formation Effects 0.000 description 3
238000004590 computer program Methods 0.000 description 3
201000001981 dermatomyositis Diseases 0.000 description 3
238000013461 design Methods 0.000 description 3
238000007877 drug screening Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
208000016361 genetic disease Diseases 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
229940027941 immunoglobulin g Drugs 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000005291 magnetic effect Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
239000003068 molecular probe Substances 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
229930014626 natural product Natural products 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
229940124531 pharmaceutical excipient Drugs 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
208000005987 polymyositis Diseases 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
235000019515 salmon Nutrition 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
108060008226 thioredoxin Proteins 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
102100036664 Adenosine deaminase Human genes 0.000 description 2
206010001367 Adrenal insufficiency Diseases 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
241000893512 Aquifex aeolicus Species 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
208000004300 Atrophic Gastritis Diseases 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
208000023328 Basedow disease Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006811 Bursitis Diseases 0.000 description 2
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
108020004394 Complementary RNA Proteins 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
241000701867 Enterobacteria phage T7 Species 0.000 description 2
206010014950 Eosinophilia Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
206010015226 Erythema nodosum Diseases 0.000 description 2
206010049466 Erythroblastosis Diseases 0.000 description 2
208000032027 Essential Thrombocythemia Diseases 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
208000036495 Gastritis atrophic Diseases 0.000 description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
208000024869 Goodpasture syndrome Diseases 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
206010061201 Helminthic infection Diseases 0.000 description 2
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
101000674009 Homo sapiens Threonine-tRNA ligase 1, cytoplasmic Proteins 0.000 description 2
101000839330 Homo sapiens Threonine-tRNA ligase 2, cytoplasmic Proteins 0.000 description 2
101000658120 Homo sapiens Threonine-tRNA ligase, mitochondrial Proteins 0.000 description 2
101000641003 Homo sapiens Tyrosine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
101000788997 Homo sapiens Tyrosine-tRNA ligase, mitochondrial Proteins 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
208000029523 Interstitial Lung disease Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
206010025327 Lymphopenia Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000002231 Muscle Neoplasms Diseases 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
208000002471 Penile Neoplasms Diseases 0.000 description 2
206010034299 Penile cancer Diseases 0.000 description 2
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102100026126 Proline-tRNA ligase Human genes 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
206010037075 Protozoal infections Diseases 0.000 description 2
108020004518 RNA Probes Proteins 0.000 description 2
239000003391 RNA probe Substances 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
208000033464 Reiter syndrome Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
206010061934 Salivary gland cancer Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
241000710960 Sindbis virus Species 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
208000000277 Splenic Neoplasms Diseases 0.000 description 2
201000002661 Spondylitis Diseases 0.000 description 2
108091027544 Subgenomic mRNA Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
208000005400 Synovial Cyst Diseases 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
208000000728 Thymus Neoplasms Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
201000011032 Werner Syndrome Diseases 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
108020002494 acetyltransferase Proteins 0.000 description 2
102000005421 acetyltransferase Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000017733 acquired polycythemia vera Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
208000017515 adrenocortical insufficiency Diseases 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
230000006229 amino acid addition Effects 0.000 description 2
206010002022 amyloidosis Diseases 0.000 description 2
208000003455 anaphylaxis Diseases 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000008236 biological pathway Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000000625 blastula Anatomy 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
238000005251 capillar electrophoresis Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000005081 chemiluminescent agent Substances 0.000 description 2
201000001352 cholecystitis Diseases 0.000 description 2
238000003200 chromosome mapping Methods 0.000 description 2
208000016644 chronic atrophic gastritis Diseases 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000024558 digestive system cancer Diseases 0.000 description 2
239000000539 dimer Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000000295 emission spectrum Methods 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
108700004025 env Genes Proteins 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000000232 gallbladder Anatomy 0.000 description 2
239000007789 gas Substances 0.000 description 2
201000010231 gastrointestinal system cancer Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
102000054767 gene variant Human genes 0.000 description 2
235000003869 genetically modified organism Nutrition 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
201000010235 heart cancer Diseases 0.000 description 2
208000024348 heart neoplasm Diseases 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
208000002551 irritable bowel syndrome Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000029226 lipidation Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
231100001023 lymphopenia Toxicity 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000000329 molecular dynamics simulation Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
201000002077 muscle cancer Diseases 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
206010028537 myelofibrosis Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
244000045947 parasite Species 0.000 description 2
230000000849 parathyroid Effects 0.000 description 2
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
244000052769 pathogen Species 0.000 description 2
210000003899 penis Anatomy 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
208000037244 polycythemia vera Diseases 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000007639 printing Methods 0.000 description 2
108010042589 prolyl T RNA synthetase Proteins 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
208000002574 reactive arthritis Diseases 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
210000003079 salivary gland Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000010703 silicon Substances 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
201000002471 spleen cancer Diseases 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
208000001608 teratocarcinoma Diseases 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
206010043554 thrombocytopenia Diseases 0.000 description 2
201000009377 thymus cancer Diseases 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
231100000167 toxic agent Toxicity 0.000 description 2
230000008791 toxic response Effects 0.000 description 2
239000003440 toxic substance Substances 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
239000004474 valine Substances 0.000 description 2
235000012431 wafers Nutrition 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
238000001086 yeast two-hybrid system Methods 0.000 description 2
KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-FXLFCPKBSA-N (2S)-(214C)azolidine-2-carboxylic acid Chemical compound N1[14C@@H](CCC1)C(=O)O ONIBWKKTOPOVIA-FXLFCPKBSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000007887 Alphavirus Infections Diseases 0.000 description 1
108020005206 Amino Acyl Transfer RNA Proteins 0.000 description 1
108090000672 Annexin A5 Proteins 0.000 description 1
102000004121 Annexin A5 Human genes 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
101100001210 Arabidopsis thaliana AGT3 gene Proteins 0.000 description 1
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
239000005496 Chlorsulfuron Substances 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
241000192700 Cyanobacteria Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
206010016077 Factor IX deficiency Diseases 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical group N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
108091027874 Group I catalytic intron Proteins 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
101150027427 ICP4 gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
102100036015 Isoleucine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
108700005090 Lethal Genes Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000589195 Mesorhizobium loti Species 0.000 description 1
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
108010003060 Methionine-tRNA ligase Proteins 0.000 description 1
101710187021 Methionine-tRNA ligase, mitochondrial Proteins 0.000 description 1
102100025860 Methionine-tRNA ligase, mitochondrial Human genes 0.000 description 1
102000000362 Methionyl-tRNA synthetases Human genes 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
108700005084 Multigene Family Proteins 0.000 description 1
206010051141 Myeloblastoma Diseases 0.000 description 1
102400000569 Myeloperoxidase Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
240000002853 Nelumbo nucifera Species 0.000 description 1
235000006508 Nelumbo nucifera Nutrition 0.000 description 1
235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241001028048 Nicola Species 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000881705 Porcine endogenous retrovirus Species 0.000 description 1
101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
101710083944 Probable methionine-tRNA ligase, mitochondrial Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
241001148023 Pyrococcus abyssi Species 0.000 description 1
238000010802 RNA extraction kit Methods 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000242678 Schistosoma Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010043189 Telangiectasia Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
108010029287 Threonine-tRNA ligase Proteins 0.000 description 1
102100028196 Threonine-tRNA ligase 2, cytoplasmic Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
206010051512 Viral myositis Diseases 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
229960003669 carbenicillin Drugs 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000003795 desorption Methods 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000007878 drug screening assay Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000000975 dye Substances 0.000 description 1
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
210000001705 ectoderm cell Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
210000004039 endoderm cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000005183 environmental health Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003499 exocrine gland Anatomy 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000009429 hemophilia B Diseases 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
238000012203 high throughput assay Methods 0.000 description 1
101150113423 hisD gene Proteins 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
101710130522 mRNA export factor Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000000260 male genitalia Anatomy 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
210000001704 mesoblast Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
238000012775 microarray technology Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
229940125645 monoclonal antibody drug Drugs 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000002346 musculoskeletal system Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
210000004287 null lymphocyte Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
238000000206 photolithography Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009993 protective function Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000009712 regulation of translation Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
238000010187 selection method Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
210000000697 sensory organ Anatomy 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000013179 statistical model Methods 0.000 description 1
210000001548 stomatognathic system Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
101150081616 trpB gene Proteins 0.000 description 1
101150111232 trpB-1 gene Proteins 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP2002509465A 2000-07-07 2001-06-29 アミノアシルｔＲＮＡシンテターゼ Pending JP2004516009A (ja)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US21674800P	2000-07-07	2000-07-07
US21901900P	2000-07-18	2000-07-18
US22305800P	2000-08-04	2000-08-04
US23469300P	2000-09-21	2000-09-21
US23979700P	2000-10-11	2000-10-11
PCT/US2001/020723 WO2002004611A2 (fr)	2000-07-07	2001-06-29	Aminoacyl arnt synthetases

Publications (1)

Publication Number	Publication Date
JP2004516009A true JP2004516009A (ja)	2004-06-03

Family

ID=27539739

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002509465A Pending JP2004516009A (ja)	2000-07-07	2001-06-29	アミノアシルｔＲＮＡシンテターゼ

Country Status (5)

Country	Link
EP (1)	EP1299546A2 (fr)
JP (1)	JP2004516009A (fr)
AU (1)	AU2001271620A1 (fr)
CA (1)	CA2413810A1 (fr)
WO (1)	WO2002004611A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011525178A (ja) *	2008-06-11	2011-09-15	エータイアーファーマ，インコーポレイテッド	チロシル−ｔＲＮＡシンテターゼポリペプチドの血小板新生活性
US9714419B2 (en)	2011-08-09	2017-07-25	Atyr Pharma, Inc.	PEGylated tyrosyl-tRNA synthetase polypeptides

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009540850A (ja)	2006-06-28	2009-11-26	インスティテューシオカタラーナデレセルカイエステュディスアバンサッツ（イセエレエア）	新規薬剤の同定のためのスクリーニング方法
US8828395B2 (en)	2009-12-11	2014-09-09	Atyr Pharma, Inc.	Antibodies that bind tyrosyl-tRNA synthetases
AU2011293294B2 (en)	2010-08-25	2016-03-24	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5759833A (en) *	1994-05-27	1998-06-02	Cubist Pharmaceuticals, Inc.	Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
CN1297044A (zh) *	1999-11-22	2001-05-30	上海博容基因开发有限公司	一种新的多肽——人甲硫氨酰tRNA合成酶29和编码这种多肽的多核苷酸
WO2001053471A1 (fr) *	2000-01-24	2001-07-26	Smithkline Beecham Corporation	Polypeptide metrs appartenant aux arnt-synthetases

2001
- 2001-06-29 JP JP2002509465A patent/JP2004516009A/ja active Pending
- 2001-06-29 WO PCT/US2001/020723 patent/WO2002004611A2/fr not_active Ceased
- 2001-06-29 EP EP01950652A patent/EP1299546A2/fr not_active Withdrawn
- 2001-06-29 AU AU2001271620A patent/AU2001271620A1/en not_active Abandoned
- 2001-06-29 CA CA002413810A patent/CA2413810A1/fr not_active Abandoned

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011525178A (ja) *	2008-06-11	2011-09-15	エータイアーファーマ，インコーポレイテッド	チロシル−ｔＲＮＡシンテターゼポリペプチドの血小板新生活性
US9499810B2 (en)	2008-06-11	2016-11-22	Atyr Pharma, Inc.	Thrombopoietic activity of tyrosyl-tRNA synthetase polypeptides
US9714419B2 (en)	2011-08-09	2017-07-25	Atyr Pharma, Inc.	PEGylated tyrosyl-tRNA synthetase polypeptides

Also Published As

Publication number	Publication date
WO2002004611A3 (fr)	2003-01-03
EP1299546A2 (fr)	2003-04-09
AU2001271620A1 (en)	2002-01-21
WO2002004611A2 (fr)	2002-01-17
CA2413810A1 (fr)	2002-01-17

Publication	Publication Date	Title
US20040018505A1 (en)	2004-01-29	Aminoacyl trna synthetases
JP2004510407A (ja)	2004-04-08	アミノアシルｔＲＮＡ合成酵素
US20040048290A1 (en)	2004-03-11	Aminoacyl trna synthetases
JP2004537270A (ja)	2004-12-16	アミノアシルｔＲＮＡ合成酵素
JP2003533967A (ja)	2003-11-18	ヒトシンセターゼ
EP1196575A2 (fr)	2002-04-17	Proteines associees de liaison gtp
JP2004500114A (ja)	2004-01-08	転写因子
JP2004518402A (ja)	2004-06-24	分泌タンパク質
JP2003530079A (ja)	2003-10-14	ヒトトランスフェラーゼ分子
JP2004528805A (ja)	2004-09-24	タンパク質ホスファターゼ
JP2005503751A (ja)	2005-02-10	細胞外マトリックスおよび細胞接着分子
EP1179065A2 (fr)	2002-02-13	Molecules completes exprimees dans des tissus humains
JP2004529603A (ja)	2004-09-30	アデニリルシクラーゼ及びグアニリルシクラーゼ
JP2004516009A (ja)	2004-06-03	アミノアシルｔＲＮＡシンテターゼ
JP2004511208A (ja)	2004-04-15	Ｒｎａ代謝タンパク質
JP2004500818A (ja)	2004-01-15	ホスホジエステラーゼ
US20050227277A1 (en)	2005-10-13	Apoptosis proteins
JP2003533975A (ja)	2003-11-18	分泌性蛋白
JP2003526340A (ja)	2003-09-09	イソメラーゼタンパク質
JP2004500813A (ja)	2004-01-15	小胞輸送タンパク質
JP2004519217A (ja)	2004-07-02	微小管関連タンパク質およびチューブリン
JP2004501610A (ja)	2004-01-22	Ｇタンパク質関連分子
JP2004528813A (ja)	2004-09-24	リポカリン
JP2003527116A (ja)	2003-09-16	ヒト免疫応答タンパク質
JP2004501632A (ja)	2004-01-22	ヒトリアーゼ